---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026356"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:10:47.111345+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCardia and CART-Tech enter exclusive pact for Heart3D Fusion Imaging

## Summary
- Exclusive development/commercialization agreement for Heart3D Fusion Imaging, enhancing 2D x-rays with 3D anatomical models.
- BioCardia gets exclusive global rights for biotherapeutic delivery and US rights for cardiac biopsy distribution.
- Management estimates $100M annual revenue potential from Heart3D if single large-market biologic becomes standard of care.
- Cross-licensing: BioCardia licenses CART-Tech IP for biotherapeutic intervention; CART-Tech licenses BioCardia IP for CRT.
- Heart3D initially sold as research tool for preclinical studies, later for clinical practice.

## SEC filing metadata
- accession: 0001437749-25-026356
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925026356/0001437749-25-026356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925026356/bcda20250812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026356
- JSON: https://secwatch.observer/filing/0001437749-25-026356.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.